Phase 2Data readout

Alisertib

ER+/HER2- breast cancer, Breast cancer, Cancer

PBYIPuma Biotechnology

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: Alisertib
Development stage: Phase 2
Event type: Data readout
Indication: ER+/HER2- breast cancer, Breast cancer, Cancer

Research summary

What is being tracked?

This catalyst tracks a Phase 2 data readout for Alisertib in ER+/HER2- breast cancer, Breast cancer, Cancer. The expected timing is based on the latest available company guidance and may change.

Development notes

ALISCA™-Breast1. 11/20/24- Initiated trial. Initial data in 2025. 11/06/25:- Interim Ph2 data presentation in H1 2026. 02/26/26:- Q2 2026 interim ALISCA-Breast1 data and Q4 2026 updated data presentations planned. 05/07/26:- H2 2026 enrollment expansion and Q4 2026 updated ALISCA-Breast1 data presentation reiterated. 08/06/26:- ALISCA-Breast1 enrollment expansion expected H2 2026; updated Ph2 data expected Q4 2026.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source